Atea Pharmaceuticals, Inc. (AVIR) Return on equity 2021–2022
Atea Pharmaceuticals, Inc. (AVIR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-16.3%FY2022 · since FY2021: 22.1% → -16.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -16.3% | -38.4 pp |
| FY2021 | 22.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AVIR financial trends
AVIR RevenueAVIR Net incomeAVIR Net marginAVIR Gross profitAVIR Gross marginAVIR Operating incomeAVIR Operating marginAVIR Operating cash flowAVIR Free cash flowAVIR Capital expendituresAVIR Stock buybacksAVIR Dividends paidAVIR Total assetsAVIR Total liabilitiesAVIR Shareholders’ equityAVIR overview →